Epstein-Barr virus (EBV) nuclear protein 2 (EBNA-2) is essential for B-lymphocyte growth transformation. EBNA-2 transactivates expression of the EBV latent membrane protein (LMP-1) and also transactivates expression of the B-lymphocyte proteins CD21 and CD23. In order to analyze the functional domains of EBNA-2, we constructed 11 linker-insertion and 15 deletion mutations. Each of the mutant EBNA-2 proteins localized to the nucleus, and each was expressed at levels similar to wild-type EBNA-2. Deletion of both EBNA-2 basic domains was required to prevent nuclear localization, indicating that either is sufficient for nuclear translocation. The mutant EBNA-2 genes were assayed for lymphocyte transformation after recombination with the EBNA-2-deleted P3HR-1 EBV genome and for LMP-1 transactivation following transfection into P3HR-1-infected B-lymphoma cells. Cell lines transformed by recombinant EBV carrying EBNA-2 mutations were assayed for growth properties and LMP-1, CD21, and CD23 expression. The mutational analysis indicates that at least four separate EBNA-2 domains are essential for lymphocyte transformation. Two other domains are necessary for the full transforming phenotype. Two deletion and eight linker-insertion mutations did not reduce transforming activity. Mutations which diminish or abolish lymphocyte transformation also diminish or abolish LMP-1 transactivation, respectively. Cells transformed by recombinant EBV carrying EBNA-2 genes with diminished or normal transforming activity all expressed high levels of LMP-1, CD23, and CD21. These findings suggest that transactivation of these viral and cellular genes by EBNA-2 plays a critical role in lymphocyte transformation by EBV. Furthermore, these results indicate that the transformation and transactivation functions of EBNA-2 may not be separable.
Epstein-Barr virus (EBV) causes an acute lymphoproliferative disease in immunosuppressed patients (45) , cottontop tamarins (22) , and mice with severe combined immunodeficiency (24) and is associated with Burkitt's lymphoma and nasopharyngeal carcinoma (20) . Primary B-lymphocyte infection in vitro results in expression of EBV genes and perpetual cell proliferation. The EBV genes expressed in latently infected lymphocytes encode nuclear proteins EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and EBNA-LP, latent membrane proteins LMP-1, LMP-2A, and LMP-2B, and two small RNAs (15) . These genes are likely to maintain latency or lymphocyte proliferation.
EBNA-2 is particularly interesting because it is essential for lymphocyte transformation. EBNA-2 reduces the serum requirements of rodent fibroblasts (8) and transactivates CD23 (36) , CD21 (37) , c-fgr (17) , and LMP-1 (1, 39) . Recombinant viruses with EBNA-2 deletion (6) or truncation (12) mutations fail to transform B cells. In addition, the two naturally occurring EBV types, EBV-1 and EBV-2, differ widely in their ability to growth-transform B lymphocytes (29) , and EBNA-2 is a major determinant of this typespecific difference (6) .
Other EBV genes are also likely to be essential for lymphocyte growth transformation. LMP-1 is a key mediator of EBV's effects in inducing B-lymphocyte activation and adhesion molecules (35) and is a transforming oncogene in rodent fibroblasts (3, 33, 34) . LMP-2 associates with LMP-1 and may contribute to the latter's effect (18 upregulates CD21 (37) , while EBNA-1 is necessary for EBV episome maintenance (44) .
The amino acid sequences of EBV type 1 and 2 EBNA-2 are remarkably divergent. This divergence is potentially useful for predicting essential domains of the protein. The EBV type 1 and 2 EBNA-2 proteins (7) (Fig. 1 ) consist of a slightly negatively charged, well-conserved amino terminus (amino acids 1 to 58), a polyproline domain which differs in length (amino acids 59 to 95), a short conserved charged domain (amino acids 96 to 134), a long divergent domain (amino acids 135 to 281), a moderately well conserved proline-rich domain (amino acids 282 to 330), a moderately well conserved basic domain, including an arginine-glycine repeat motif (amino acids 331 to 369), a moderately well conserved acidic domain (amino acids 370 to 475), and a short, basic, conserved carboxy terminus (amino acids 476 to 483). A portion of the acidic domain near the carboxy terminus (amino acids 457 to 469 [29a] ) is homologous to the retinoblastoma protein-interactive motif of adenovirus ElA (41) , human papillomavirus E7 (11) , and simian virus 40 (SV40) large T antigen (9) . EBNA-2 undergoes extensive posttranslational modification, including phosphorylation, and is associated with the nuclear matrix, nucleoplasm, and chromatin (26, 38) .
EBNA-2 may be essential for transformation because of its transactivating function, or transformation may be partially or completely separable from transactivation. A molecular genetic analysis of EBNA-2 transforming and transactivating functions should indicate whether the same or different EBNA-2 domains are required for these two functions. Therefore, linker-insertion and deletion mutations were constructed throughout the EBNA-2 gene so that the BamHI site of plasmid pSG5 (Stratagene).
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Plasmids containing linker-insertion mutations were constructed by cutting plasmid HK-EBNA-2 with the appropri- Transfections and infections. For production of recombinant EBV, cosmids (20 ,ug) were precipitated with plasmid pSVNaeIBamZ (40 ,ug) and transfected into P3HR-1 cells by use of an electroporator (Gene Pulser; Bio-Rad) with a pulse of 0.2 V at 960 ,uF. Four days after transfection, the virus was harvested and used to infect human umbilical cord mononuclear cells as described previously (6) . At least two separate virus preparations were obtained for each cosmid that yielded recombinant virus with transforming activity equivalent to wild-type virus; multiple virus preparations (from at least two independent bacterial clones) were obtained for each cosmid that yielded nontransforming or weakly transforming recombinant virus.
For immunoprecipitations, cosmids or plasmids (25 ,ug) were transfected into BL30/P3HR-1 cells by electroporation. After 6 days, cells were counted and equal numbers of cells were used for immunoprecipitations.
Immunoprecipitations. LMP-1 was immunoprecipitated from an aliquot of the transfected cells as described previously (39). EBNA-2 was immunoprecipitated from another aliquot of cells (containing the same number of cells as for LMP-1). For EBNA-2 immunoprecipitations, cells were pelleted, resuspended in 0.5 ml of buffer A (phosphatebuffered saline with 0.2% Nonidet P-40), 0.5 ml of buffer B (10 mM Tris [pH 8.0], 100 mM NaCl, 0.5% Nonidet P-40, 1% deoxycholate) was added, and the supernatant was sonicated. The supernatant was incubated with PE2 anti-EBNA-2 monoclonal antibody (45) for 3 h at 4°C, protein G-Sepharose 4 (Pharmacia) was added, and the incubation was continued for 30 min at 4°C. Immunoprecipitates were washed three times with buffer B, resuspended in protein gel loading buffer, boiled, and run on a polyacrylamide gel.
Immunofluorescence, immunoblotting, and flow cytometry. EBNA-2 expression was analyzed by indirect immunofluorescence microscopy with an anti-EBNA-2 monoclonal antibody (45) or by immunoblot with human serum (36) . LMP-1 was detected with the S12 anti-LMP-1 monoclonal antibody (19) . Flow cytometry for cell surface expression of CD23 was performed with monoclonal antibody EBVCS 1 (16) and for surface expression of CD21 with monoclonal antibody HB5 (31). 
RESULTS
Parent EBNA-2 gene nucleotide sequence. EBNA-2 mutants were constructed from an EBV-1 (W91 strain [21] ) cosmid DNA clone (27) . Since the degree of divergence in EBV-1 EBNA-2 gene DNA sequences is unknown, the sequence of W91 EBNA-2 was determined and compared with the previous EBV-1 (B95-8 strain) EBNA-2 sequence and the two previous EBV-2 (AG876 and Jijoye strain) EBNA-2 sequences (7, 10) . The predicted W91 EBNA-2 amino acid sequence is shown in Fig. 1 . Comparison of the W91 and B95-8 EBV-1 EBNA-2 sequences shows 38 (2.6%) nucleotide and 16 (3.3%) amino acid differences (Table 1) . W91 has a five-amino-acid deletion and a one-amino-acid insertion relative to B95-8. In contrast, the two predicted type 2 EBNA-2 amino acid sequences are identical. With the exception of amino acids 204, 485, and the amino acid insertion (between amino acids 211 and 212 of B95-8), W91 differences from B95-8 coincide with the differences between B95-8 and type 2 EBNA-2.
Lymphocyte transformation by EBV containing EBNA-2 mutations. P3HR-1 cells were used to generate recombinant EBV containing EBNA-2 mutations. These cells are infected with an EBV strain, P3HR-1, which is deleted for EBNA-2 and therefore cannot transform B lymphocytes. Transfection of these cells with EBV DNA fragments followed by induction of P3HR-1 virus replication results in homologous recombination of the viral genome with the transfected DNA (6, 12 tions can be compared with recombinant EBV with wildtype EBNA-2 (6).
The EBNA-2 linker-insertion and deletion mutations which were constructed for these experiments are shown in Fig. 2 . Each mutation was inserted into an EBV cosmid, T1EBNA-2, which substantially overlaps the EBV P3HR-1 deletion. The recombinant cosmid was transfected into P3HR-1 cells, and virus replication was induced by cotransfection with plasmid pSVNaeIBamZ. The resultant viruses, consisting of nontransforming parent EBV P3HR-1 and EBV which has undergone recombination with the transfected cosmid DNA, were used to infect primary B lymphocytes. A cosmid containing wild-type EBNA-2 was transfected in parallel with the cosmids containing mutant EBNA-2 to control for the transfection, recombination, and transformation efficiency in each experiment. The number of transforming EBV recombinants was assessed by infecting primary B lymphocytes with the recombinant virus preparation and counting the number of microwells that were positive for transformation. B lymphocytes were infected with an undiluted preparation of recombinant virus so that mutants with diminished transforming activity could be detected. At this concentration of virus, the number of microwells that were positive for transformation with recombinant EBV containing wild-type EBNA-2 was just beyond the linear range. (Fig. 3) .
Transient EBNA-2 expression from the cosmids after transfection into BL30/P3HR-1 cells was sufficient to allow quantitation of EBNA-2 expression on immunoblots after immunoprecipitation. A representative immunoblot is shown in Fig. 4 (Fig. 4) . Deletions involving the polyproline or the negatively charged carboxy-terminal region of EBNA-2 resulted in proteins with disproportionately increased electrophoretic mobility. These results are compatible with the hypothesis that the polyproline and acidic domains contribute to the slower than expected electrophoretic mobility of wild-type EBNA-2.
Induction of LMP-1 by EBNA-2 mutants. Two series of experiments were done to assay the ability of the EBNA-2 mutants to transactivate LMP-1. In the first set of experiments, cosmids containing wild-type EBNA-2, each of the EBNA-2 linker-insertion mutants, and each of the EBNA-2 deletion mutants were used. In the second set of experiments, wild-type EBNA-2 and most of the deletion mutants (especially those that failed to transform B lymphocytes) were cloned into a smaller plasmid, pZip-Neo-SV(X)1. Plasmids or cosmids containing wild-type or mutant EBNA-2 were transfected into BL30/P3HR-1 cells, and transactivation of the P3HR-1 LMP-1 gene was assayed by immunoprecipitation and immunoblot. Experiments with plasmids and cosmids were each done in triplicate; thus, a total of six independent experiments were performed for each of the mutants shown in Fig. 5 . The relative amounts of LMP-1 expressed with each of the mutants was consistent between experiments; however, the absolute amount of LMP-1 expressed varied between experiments. Therefore, LMP-1 was not quantitated directly but was graded from 0 to 5+ relative to transactivation with the vector control (0+) or with wild-type EBNA-2 (4+). Levels of LMP-1 transactivation (relative to wild-type EBNA-2) obtained for EBNA-2 mutants were similar for cosmid and plasmid vectors; however, the transfection efficiency with the plasmid vector (2 to 5%) was higher than with the cosmid vector (0.5 to 2%). An immunoblot of immunoprecipitations from transfections with each of the plasmids is shown in Fig. 5 .
LMP-1 transactivation generally correlated with transforming activity for each of the mutants ( (Fig. 6 and 7, respectively) . EBNA-1 (Fig. 6 ) is a useful internal control for the amount of protein loaded in these immunoblots. While the IB4, P3HR-1, deletion mutant [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , and mutant 143-230 samples are slightly overloaded relative to most of the others, the level of LMP-1 expression in the cell lines containing the EBNA-2 mutants was at least as high as the level in the wild-type EBNA-2 recombinant. Thus, the LMP-1 transactivation activity of the EBNA-2 mutants in transient assays did not always correlate with the level of LMP-1 expression in lymphoblastoid cell lines derived from the mutants.
The level of EBNA-2 in all of the cell lines was similar except for TlEBNA-2d463-483. The apparent low level of expression of this mutation in both transient transfection (Fig. 4) and stable cell lines (Fig. 6) TlEBNA-2d463-483 and the other mutants was less evident when EBNA-2 was detected by immunofluorescence with the monoclonal antibody to EBNA-2.
Induction of CD23 and CD21 by EBNA-2 mutants. Lymphoblastoid cell lines transformed by recombinant EfB containing EBNA-2 mutations were also analyzed for CD23 and CD21 expression because these B-cell activation molecules are induced by EBNA-2 (36, 37) . All of the trans- formed lymphoblastoid cell lines showed high-level CD23 and CD21 surface expression. There was substantial quantitative variation in the high CD21 and CD23 expression levels both among different mutants and in different lymphoblastoid cell lines derived from the same mutant (data not shown). (14, 35a) . Second, LMP-1 transactivation by EBNA-2 is somewhat species and tissue specific and is most evident in human B lymphocytes (39 (43) . Since deletion of the carboxy portion of adenovirus ElA domain 2 does not affect binding to these cell proteins, the absence of an effect of the homologous EBNA-2 deletion (amino acids 463 to 483) might be expected and does not exclude the possibility that EBNA-2 might interact with these cell proteins. Deletion of the EBNA-2 sequence immediately amino terminal to amino acid 463 abolishes transformation, as is observed with deletion of the amino-terminal portion of adenovirus ElA domain 2. However, these latter sequences of EBNA-2 and adenovirus ElA are only weakly homologous.
Analysis of amino acid sequences and phenotypic characteristics which are common or specific to EBV-1 and EBV-2 EBNA-2 genes are also useful for relating primary sequence to function. Fifty-six percent of the predicted amino acid sequence is identical in type 1 and type 2 EBV EBNA-2 (as is indicated in Fig. 1 ). Type-common sequences are likely to be important in the phenotypic features shared by type 1 and type 2 EBV, including B-lymphocyte transformation and LMP-1, CD23, and CD21 transactivation. Similarly, typespecific sequences are likely to be important in the transforming and transactivation phenotypes specific for type 1 or type 2 EBV. Compared with type 1 EBV, type 2 EBV has a lower transforming efficiency, poorer initial outgrowth, and higher cell density dependence for cell viability. Compared with type 1 EBNA-2, type 2 EBNA-2 also has less effect in transactivating CD21 or CD23 expression in stably transfected cell lines (37) , and EBV type 2 transformants are more variable in CD23 expression (6) . However, type 2 EBNA-2 does not differ from type 1 EBNA-2 in LMP-1 transactivation in acute transfection experiments (39) or in transformed cell lines (6) . These type-common and type-specific effects are compatible with the working hypothesis that transformation and transactivation are closely linked and that transformation or CD21 and CD23 transactivation may be partly affected by type-specific EBNA-2 domains that are not involved in LMP-1 transactivation.
